共 25 条
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France
被引:30
|作者:
Maza, A.
[1
]
Richard, M. A.
[2
]
Aubin, F.
[3
]
Ortonne, J. P.
[4
]
Prey, S.
[5
,6
]
Bachelez, H.
[7
]
Beylot-Barry, M.
[5
,6
]
Bulai-Livideanu, C.
[1
]
Lahfa, M.
[1
]
Nougue, J.
[8
]
Mengual, X.
[9
]
Le Moigne, M.
[1
]
Lauwers-Cances, V.
[10
]
Paul, C.
[1
]
机构:
[1] Univ Toulouse 3, Serv Dermatol, Hop Larrey, UMR CNRS INSERM 1056 5165, F-31062 Toulouse, France
[2] Aix Marseille Univ, UMR 911, Inserm CRO2, F-13385 Marseille, France
[3] Univ Franche Comte, F-25030 Besancon, France
[4] CHU Nice, Hop Archet 2, Serv Dermatol, Nice, France
[5] CHU Bordeaux, EA 2406, Serv Dermatol, F-33000 Bordeaux, France
[6] Univ Bordeaux Segalen, F-33000 Bordeaux, France
[7] Hop St Louis, Serv Dermatol, F-75475 Paris, France
[8] Ctr Hosp Montauban, Serv Dermatol, Montauban, France
[9] Statitec, Labege, France
[10] CHU Toulouse, Serv Epidemiol, Toulouse, France
关键词:
PHASE-III TRIAL;
PATIENT-MEMBERSHIP SURVEY;
QUALITY-OF-LIFE;
DOUBLE-BLIND;
ALEXITHYMIA;
IMPACT;
ADALIMUMAB;
DEPRESSION;
EFFICACY;
BURDEN;
D O I:
10.1111/j.1365-2133.2012.10991.x
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background There is a low rate of systemic treatment usage in moderate to severe psoriasis. Objectives The primary objective of the present study was to assess the time period between lack of control of moderate to severe psoriasis with topical treatment or phototherapy as perceived by patients and the medical decision to introduce a systemic treatment. Methods This was a prospective multicentre study, which included patients with moderate to severe psoriasis. A standardized questionnaire was completed by physicians and patients at the time the decision was taken to introduce a systemic treatment. The primary outcome was the duration of uncontrolled psoriasis, as estimated by the patient, prior to the introduction of systemic treatment. Factors associated with a delay in systemic treatment defined as > 2 years of uncontrolled psoriasis were assessed. The agreement between patients and physicians on the duration of uncontrolled psoriasis was estimated. Results The study included 142 patients. The mean age was 48 years, the mean Psoriasis Area and Severity index (PASI) was 18.5 and the mean Dermatology Life Quality Index (DLQI) was 12. The median duration of uncontrolled psoriasis estimated by patients and physicians was 3 years and 2 years, respectively. Factors associated with a delay in the introduction of systemic treatment as assessed by patients were fewer than three physician visits since psoriasis was uncontrolled [odds ratio (OR) 3.05; 95% confidence interval (CI) 1.29-7.21], Hospital Anxiety and Depression (HAD) scale < 10 (OR 2.83; 95% CI 1.19-6.71), continuous psoriasis evolution (OR 2 67; 95% CI 1.12-6.42), low consumption of topical treatment (OR 2.35; 95% CI 1.03-5.34). Conclusions There is a significant delay in the introduction of systemic treatment in moderate to severe psoriasis. Patients with low level anxiety and limited use of healthcare resources appear to be at higher risk of experiencing long delays.
引用
收藏
页码:643 / 648
页数:6
相关论文